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Abstract
Background:
investigated the association between serum 25-hydroxyvitamin D (25OHD) levels and physical performance in older adults.
Methods: 2694 community-dwelling elderly women and men from the Progetto Veneto Anziani (Pro.V.A.) were included.
Physical performances were assessed by: tandem test, 5 timed chair stands (TCS), gait speed, 6-minute walking (6 mW)
distance, handgrip strength, and quadriceps strength. For each test, separate general linear models and loess plots were
obtained in both genders, in relation to serum 25OHD concentrations, controlling for several potential confounders.
Results: Linear associations with 25OHD levels were observed for TCS, gait speed, 6 mW test and handgrip strength, but not
for tandem test and quadriceps strength. After adjusting for potential confounders, linear associations with 25OHD levels
were still evident for the 6 mW distance in both genders (p=.0002 in women; ,.0001 in men), for TCS in women (p=.004)
and for gait speed (p=.0006) and handgrip strength (p=.03) in men. In loess analyses, performance in TCS in women, in
gait speed and handgrip strength in men and in 6 mW in both genders, improved with increasing levels of 25OHD, with
most of the improvements occurring for 25OHD levels from 20 to 100 nmol/L.
Conclusion: lower 25OHD levels are associated with a worse coordination and weaker strength (TCS) in women, a slower
walking time and a lower upper limb strength in men, and a weaker aerobic capacity (6 mW) in both genders. For optimal
physical performances, 25OHD concentrations of 100 nmol/L appear to be more advantageous in elderly men and women,
and Vitamin D supplementation should be encouraged to maintain their 25OHD levels as high as this threshold.
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Introduction
Aging people develop mobility impairment as a first step in the
disablement process [1]. Given the rising numbers of elderly
people, there is an increasing need to identify modifiable risk
factors of mobility impairment in order to prevent or delay
disability onset.
In the past two decades, it has become evident that the role of
vitamin D extends beyond calcium homeostasis [2]. Experimental
studies have revealed vitamin D receptors (VDR) in skeletal
muscle [3,4], and vitamin D metabolites have been found to affect
muscle metabolism by stimulating de novo protein synthesis,
increasing the proportion of type II muscle fibers and improving
muscle function [5–7]. Clinical studies on older people have shown
that low serum levels of 25-hydroxyvitamin D (25OHD) correlate
with a decrease in lower-extremity muscle strength and poorer
performances in rising from a chair [8–11]. However, several
other studies failed to show any association between vitamin D
status and motor performance measures [12–15]. Controversial
findings may result from differences in the number and type of
performance tests considered, and an inadequate control over
potential confounders that might impair physical performance. As
an example, in several studies analyses were not stratified by
gender, or they were only performed in women [10,11,16],
introducing a significant bias since women perform less well than
men, and they have lower vitamin D levels [17]. In addition, most
of the studies supporting the association between vitamin D and
physical performance limited their analysis to two or three tests,
such as chair stands or gait tests [10,11,16–19], which are not
representative of global muscle function. Another bias concerns
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The role of Vitamin D in musculoskeletal functionality among elderly people is still controversial. Wethe application of vitamin D cut-offs usually established to define
the risk for osteoporosis, which are not expected to define mobility
risk [10,20]. Finally, several studies failed in controlling for
confounders such as depression and cognitive impairments, two
chronic conditions with a relevant impact on elderly people’s
performance [10,11,17,19,20]. The association between serum
25OHD concentrations and physical performance thus remains
controversial and a consensus on which 25OHD levels are
adequate for mobility function in older-aged people is still lacking.
The first aim of the present study was to ascertain the
association between vitamin D status and mobility in a large
sample of Italian older people by testing the relationship between
their 25OHD serum levels and a large battery of physical
performance tests, exploring balance, gait speed, coordination,
upper and lower limb strength and aerobic capacity. The second
aim was to identify an adequate serum 25OHD level for
musculoskeletal functions in elderly men and women.
Methods
Data Source and Subjects
Data for this analysis are from the Progetto Veneto Anziani
(Pro.V.A.), an observational cohort study on the Italian population
aged $65 yrs, living in two geographical areas in the North-East
of Italy (Camposampiero and Rovigo). The study population
included 3099 age- and sex-stratified Caucasian participants (1245
men and 1854 women), who were randomly selected between
1995 and 1997, using a multistage stratified method. Sampling
procedures and data collection methods have been described
elsewhere [21]. Participants were examined at the clinics by
trained physicians and nurses. Disease status was determined by
integrating information from physical examination and medical
records review. Disability was defined as the inability to perform 1
or more of the activities of daily living (ADLs): bathing, dressing,
eating, using the toilet, or transferring. Participants who lacked
serum 25OHD values (n=272), those in wheel chairs or unable to
walk (n=89), or with leg and/or arm amputations (n=23), and
cases of hyperparathyroidism – defined as serum calcium levels
.10.5 mg/dl and parathyroid hormone (PTH) levels .55 ng/L
(n=21) – were ruled out. The final sample consisted of 2694
subjects whose data on physical performance were complete. The
local ethical committees of Padua University and of the Local
Health Units (USSL) n. 15 and n. 18 of the Veneto Region
approved the study protocol, and participants gave their written
informed consent. Subjects unable to give their informed consent
were not enrolled.
Physical performance measures
Physical performance measures were assessed using standard-
ized performance tests [21]:
N Tandem test (static balance ability): participants were asked to
maintain balance in three different positions: a side-by-side
position, a semi tandem position, and a full-tandem position.
The amount of time they succeeded in remaining so, in
seconds, was recorded;
N 5 timed chair stands, TCS (coordination and strength):
participants were asked to stand up and sit down 5 times as
quickly as possible, with their hands folded across their chest;
the time taken to complete the test, in seconds, was recorded;
N Gait speed: the best performance achieved in two walks at
usual pace along a 4m corridor was recorded in meter/
seconds. Participants were allowed to use canes or walkers;
N 6-minute walking test, 6 mW (aerobic capacity): participants
were asked to walk at their usual pace for 6 minutes, recording
the distance they covered in meters [22];
N Handgrip and quadriceps strength: handgrip strength, in kg,
was measured using a JAMAR hand-held dynamometer (BK-
7498, Fred Sammons, Inc.). The best result obtained at two
attempts with each hand was used for analyses. Knee extensor
(quadriceps) and hip flexor (iliopsoas) muscle strengths were
determined using a Nicholas Manual dynamometer (BK-7454,
Fred Sammons, Inc.). Quadriceps strength, in Newton, was
determinate in the dominant leg [23].
Biochemical measurements
Venous blood samples were obtained after an overnight fast,
centrifuged and stored at 280uC. Routine biochemical tests were
performed at the city hospitals, whereas PTH and 25OHD tests
were performed at the university laboratory of Padua. Serum
25OHD levels were measured by radioimmunoassay (RIA kit;
DiaSorin). The intra-assay and interassay coefficients of variation
for 25OHD were 8.1% and 10.2%, respectively. Serum intact
PTH levels were measured using a two-site immunoradiometric
assay kit (N-tact PTHSP; DiaSorin): the intra-assay and interassay
coefficients of variation for PTH were 3.0% and 5.5%, re-
spectively. Serum creatinine was measured using a standard
creatinine Jaffe method (Roche Diagnostics, Germany) and
glomerular filtration rate (GFR) was calculated with the MDRD
formula. Serum albumin was measured using an agarose
electrophoretic technique (Hydragel Protein(E) 15/30; Sebia,
France).
Statistical analyses
Participants’ characteristics were summarized using means (6
standard deviations) for continuous variables and counts and
percentages for categorical variables. Given the gender-related
differences, all data analyses were stratified by sex. Means and
proportions were calculated for sex-specific quintiles of the
distribution of 25OHD serum levels. For continuous variables
normal distributions were tested using the Shapiro Wilk test.
Differences in categorical variables were examined using the Chi-
square test. Age-adjusted p values for trends were calculated,
checking the differences between means of covariates by quintiles
of vitamin D status using analysis of variance (ANOVA). General
linear models (GLM) were used to examine the independent
association between 25OHD levels and performance tests. The
association between performance and vitamin D status was tested
considering 25OHD levels both as a continuous variable (per unit
of 25OHD) and as a categorical variable (sex-specific quintiles).
The presence of a nonlinear (quadratic) effect of 25OHD
concentrations was examined but did not emerge, so only the
linear associations were modeled. Known factors associated with
25OHD levels and/or physical functionality were examined for
inclusion in the analyses and two multivariate models were
obtained. Age, smoking habit (never/former vs current smoker),
body mass index (BMI; calculated as the weight in kg/height in
meters squared), physical activity (defined as $4 h/week in the
previous month of at least moderate physical activity, e.g. brisk,
walking, cycling, swimming, dancing, gardening or physical
exercising), cognitive impairment (Indexed Mini-Mental State
Examination score ,0.8; [24]), depression (defined as a score $11
on the Geriatric Depression Scale [25]), season of the year
(November–February vs March–October) and GFR were added
as confounders in the first model (Model 1). Among adjudicated
diagnoses of cardiovascular diseases (CVD: coronary heart disease,
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disease, hypertension), diabetes, chronic obstructive pulmonary
disease (COPD), osteoarthritis (including hand/knee/hip osteoar-
throsis, hip fracture), neurodegenerative diseases (Parkinson,
dementia), cancer, and visual impairments, those with a p-value
,.10 at bivariate analysis (i.e. CVD, osteoarthritis, COPD and
visual impairment) were considered as covariates and added into
Model 2, including both confounders and covariates. Also
variables that could act as intermediate factors of altered
25OHD levels- i.e. PTH concentrations and osteoporosis- were
added to Model 2. To identify the best 25OHD levels for
musculoskeletal functions in the elderly men and women, we
conducted a loess analysis, where loess smoother is a form of
locally weighted regression line using a weighted average of a set of
data points at each part of the curve and is robust to outlying
values. The procedure, applied to the whole data set in both
genders, included the same variables as the multivariate models.
All analyses were performed using the SAS rel. 9.13 (Cary NC:
SAS institute). All statistical tests were two-tailed and statistical
significance was assumed for a p-value ,.05.
Results
Participants’ characteristics
The sample consisted of 2694 community-dwelling elderly
subjects (1597 F and 1097 M). They were not currently disabled in
ADLs. Their mean age (6SD) was 75.6 y (67.5; range 65–98 y) in
women, and 76.2 y (67.8; range 65–99) in men. The mean serum
25OHD level was 65.0 nmol/L (641.3; range: 2.5–329) in
women, and 101.9 nmol/L (662.4; range: 2.5–441) in men.
Vitamin D deficiency, often defined as a serum 25OHD level
,50 nmol/L [26], was present approximately in the 40% of the
women and in the 20% of the men; whereas severe deficiency
(25OHD ,25 nmol/L; [26]) was identified in 13.5% of women
and 5.9% of men.
The age-adjusted characteristics of the participants, classified by
the quintiles of their 25OHD levels, are shown in Tables 1 and 2,
respectively for women and men. Participants in the lowest
25OHD quintile were significantly older than those with higher
levels of 25OHD (p for trend ,.0001). After adjusting for age, both
male and female participants in the lowest quintiles were
significantly less active, more depressed and more cognitively
impaired than participants in the highest quintiles.
Association between 25OHD levels and performance
measure
The age-adjusted mean physical performance measures by
25OHD quintiles are shown for women and men in Tables 3 and
4, respectively. No differences in 25OHD quintiles emerged for
tandem test performance and quadriceps strength in either gender,
so these tests were excluded from further analyses. Significant
linear associations were found for TCS test (p for trend ,.0001 in
women;.03 in men), gait speed and 6 mW test (p for trend ,.0001,
in both genders), and for handgrip strength (p for trend ,.0009 in
women; ,.0001 in men). The multivariate adjusted mean
measures obtained for these performance tests are shown in
Tables 5 and 6, for women and men respectively. After controlling
Table 1. Participants’ characteristics by serum 25-hydroxyvitamin D (25OHD) quintiles in women: the PRO.V.A. Study.
25OHD quintiles (nmol/L)
#32 (n=339)
.32 & #49
(n=315)
.49 & #68
(n=322)
.68 & #93
(n=304) .93 (n=317)
Age-adjusted p for
trend
Age (yrs) 79.9(7.5) 76.4(7.7) 75.2(6.9) 73.5(6.6) 72.4(6.0) ,.0001 (unadjusted)
BMI (kg/m
2) 27.9(5.3) 28.1(5.1) 28.0(4.5) 28.5(4.7) 27.7(4.5) .03
Current smokers, % 6.8 4.4 7.4 6.2 4.4 .01
Regular activity,% 49.6 62.4 67.3 77.2 80.2 ,.0001
Depression,% 50.5 41.0 37.5 33.8 37.6 .07
MMSE ratio 0.72(0.23) 0.77(0.17) 0.79(0.16) 0.82(0.14) 0.83(0.13) .006
Cardiovascular diseases, % 31.6 21.7 16.5 14.9 12.0 .003
Neuro-degenerative diseases,% 18.3 9.2 6.8 4.6 3.5 .03
Osteoarticular diseases,% 78.6 73.5 72.4 63.5 65.2 .03
Any cancer,% 7.1 8.6 6.5 6.2 7.3 .97
Visual impairments,% 36.6 26.0 23.6 20.0 18.3 .05
Diabetes,% 13.3 10.8 9.6 8.9 8.5 .10
COPD,% 7.1 7.9 3.4 4.3 2.8 .005*
Serum levels
Calcium (mg/dl) 9.4(2.4) 9.4(0.4) 9.4(0.4) 9.7(5.7) 9.5(0.43) .49
PTH (ng/L) 56.4(43.1) 44.6(20.6) 42.6(21.0) 39.4(18.9) 36.3(31.5) ,.0001
GFR (ml/min/1.73 m
2) 64.5(19.0) 65.9(20.2) 65.9(16.9) 67.9(17.3) 68.9(16.1) .88
Albumin (g/dL) 4.22(0.40) 4.32(0.47) 4.33(0.36) 4.36(0.31) 4.38(0.35) .005
25OHD (nmol/L) 20.4(7.8) 41.2(4.9) 58.5(5.3) 80.1(7.2) 128.5(37.8)
*also adjusted for smoking habit; BMI (body mass index), MMSE (Mini-Mental State Examination), COPD (Chronic Obstructive Pulmonary Diseases), PTH (parathyroid
hormone), GFR (glomerular filtration rate), 25OHD (serum 25-hydroxyvitamin D).
For conversion from nmol/L to ng/ml divide by 2.496.
Numbers are mean values (and Standard Deviations) or percentage (%), as appropriate.
doi:10.1371/journal.pone.0034950.t001
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25OHD quintiles (nmol/L)
# 53 (n=231)
.53 & #79
(n=212)
.79 & #103
(n=217)
.103 & #143
(n=219)
.143
(n=218)
Age-adjusted
p for trend
Age (yrs) 80.6(8.0) 76.7(8.1) 75.9(7.44) 74.0(6.9) 73.5(6.4) ,.0001
(unadjusted)
BMI (kg/m
2 ) 26.2(4.4) 26.9(4.1) 26.7(3.7) 26.6(3.3) 27.1(3.5) .83
Current smokers, % 24.2 20.3 20.7 26.5 22.5 .20
Regular activity, % 65 79.6 85.1 83.4 95.0 ,.0001
Depression, % 35.4 22.7 20.2 19.7 17.4 .002
MMSE ratio 0.74(0.21) 0.80(0.18) 0.81(0.14) 0.84(0.12) 0.84(0.11) .007
Cardiovascular diseases, % 38.7 28.4 28.1 23.8 22.6 .03
Neuro-degenerative diseases, % 20.4 10.3 1.8 3.6 2.3 ,.0001
Osteoarticular diseases, % 49.8 49.5 46.0 37.4 36.7 .09
Any cancer,% 13.0 10.0 6.4 6.8 6.4 .02
Visual impairment,% 35.2 28.9 20.7 21.5 17.0 .1
Diabetes, % 10.4 7.6 8.8 7.8 4.6 .02
COPD,% 20.3 14.6 21.2 14.2 9.2 .13
*
Serum levels
Calcium (mg/dl) 9.7(2.3) 9.3(0.6) 9.4(0.4) 10.0(8.6) 9.4(0.7) .95
PTH (ng/L) 48.3(32.8) 39.3(18.9) 39.5(18.9) 32.9(14.2) 29.4(16.5) ,.0001
GFR (ml/min/1.73 m
2) 70.2(20.3) 72.9(19.4) 74.7(19.5) 74.3(16.9) 78.4(18.5) .16
Albumin (g/dL) 4.23(0.43) 4.34(0.36) 4.38(0.34) 4.37(0.32) 4.42(0.32) .0003
25OHD (nmol/L) 34.3(14) 66.1(7.7) 91.7(7.1) 121.5(11.4) 198.8(56.5)
*also adjusted for smoking habit; BMI (body mass index), MMSE (Mini-Mental State Examination), COPD (Chronic Obstructive Pulmonary Diseases), PTH (parathyroid
hormone), GFR (glomerular filtration rate), 25OHD (serum 25-hydroxyvitamin D).
For conversion from nmol/L to ng/ml divide by 2.496.
Numbers are mean values (and Standard Deviations) or percentage (%), as appropriate.
doi:10.1371/journal.pone.0034950.t002
Table 3. Observed physical performance measures (mean [SD]) by serum 25-hydroxyvitamin D (25OHD) quintiles in women: the
Pro.V.A. Study.
25OHD quintiles
#32
(n=339)
.32 & #49
(n=315)
.49 & #68
(n=322)
.68 & #93
(n=304)
.93
(n=317)
Age- adjusted p for
trend
Performance tests
Side by side, sec 9.9(0.6) 9.9(0.4) 9.9(0.4) 9.9(0.6) 9.9(0.1) .68
Semi-tandem, sec 9.2(2.0) 9.5(1.9) 9.6(1.5) 9.7(1.4) 9.9(0.8) .07
Full tandem, sec 7.9(3.0) 8.4(2.7) 8.2(2.9) 8.3(2.9) 8.5(2.8) .30
5 timed chair
stands, sec
16.4(10.8) 14.0(6.3) 14.0(9.1) 13.1(5.2) 12.4(3.5) ,.0001
Gait speed, m/s 0.55(0.20) 0.61(0.21) 0.64(0.18) 0.67(0.18) 0.70(0.18) ,.0001
6-min walking
distance, m
221.5(117.8) 283.5(109.9) 297.3(109.1) 321.4(96.8) 332.8(86.4) ,.0001
Handgrip strength,
kg
20.0(5.8) 22.5(5.7) 23.1(6.0) 24.1(5.9) 23.9(5.6) ,.0009
Quadriceps strength
Knee extension, N 18.7(9.0) 19.9(7.6) 22.1(20.2) 21.4(8.2) 21.1(19.1) .39
Hip flexion, N 20.9(52.0) 18.2(7.11) 20.3(9.4) 20.8(8.2) 21.1(21.9) .89
doi:10.1371/journal.pone.0034950.t003
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evident for the 6 mW test in both genders (p=.0002 in women;
,.0001 in men), for the TCS test in women (p=.004), and for gait
speed (p=.0006) and handgrip strength (p=.03) in men. Further
adjustment for PTH levels and osteoporosis slightly attenuated the
associations between 25OHD levels and physical performance
measures (details not shown).
When the associations between physical performance and
vitamin D levels were examined using serum 25OHD levels as
a continuous variable, a significant linear association emerged in
the adjusted model for both genders only for the 6 mW test: the
b coefficient [SE] per unit of serum 25OHD was 0.15 [0.05] in
women, p=.007; and 0.14 [0.05] in men, p=.004. Further
adjustment for PTH levels and osteoporosis did not affect the
associations between 25OHD levels and this performance test.
Loess analyses for 25OHD levels and performance
measures
The association between 25OHD concentrations and perfor-
mance measures is shown for TCS, gait speed, 6 mW distance and
handgrip strength tests in Figures 1, 2, 3 and 4 respectively. The
time taken to complete the TCS test decreased significantly with
increasing levels of 25OHD in women only and most of the
improvements occurred between 20 to 100 nmol/L of 25OHD. In
Table 4. Observed physical performance measures (mean[SD]) by serum 25-hydroxyvitamin D (25OHD) in men: the Pro.V.A. Study.
25OHD quintiles (nmol/L)
#53
(n=231)
.53 & #79
(n=212)
.79 & #103
(n=217)
.103 & #143
(n=219)
.143
(n=218)
Age-adjusted
p for trend
Performance tests
Side by side, sec 9.9(0.6) 9.9(0.7) 10(0) 10(0) 9.9(0.6) 0.43
Semi-tandem, sec 9.6(1.4) 9.8(0.9) 9.6(1.5) 9.8(1.1) 9.8(1.1) 0.38
Full tandem, sec 8.4(3.0) 9.1(2.3) 9.0(2.3) 9.0(2.3) 9.4(1.8) 0.36
5 timed chair
stands, sec
14.5(11.8) 12.0(4.4) 12.0(4.4) 12.0(9.0) 11.0(3.2) 0.03
Gait speed, m/s 0.63(0.21) 0.72(0.20) 0.76(0.19) 0.77(0.17) 0.80(0.17) ,0.0001
6-min walking
distance, m
281.6(133.8) 345.6(119.0) 349.7(119.4) 384.1(96.3) 395.8(92.5) ,0.0001
Handgrip strength, kg 30.5(9.1) 33.8(8.7) 34.9(8.8) 37.2(8.2) 37.1(7.9) ,0.0001
Quadriceps strength
Knee extension, N 24.3(21.5) 30.2(30.8) 28.8(24.9) 31.0(24.2) 30.4(17.8) 0.26
Hip flexion, N 24.9(24.8) 31.2(31.9) 26.7(10.1) 31.2(24.1) 29.7(11.0) 0.47
doi:10.1371/journal.pone.0034950.t004
Table 5. Adjusted estimates of physical performance mean values [mean (SE)] by serum 25-hydroxyvitamin D (25OHD) in women:
the Pro.V.A Study.
FEMALE 25OHD quintiles (nmol/L)
#32 .32 & #49 .49 & #68 .68 & #93 .93 p for trend
5 timed chair stands, sec
Model 1 15.3 (0.5) 13.7 (0.4) 13.7 (0.4) 13.5 (0.4) 12.9 (0.4) .001
Model 2 15.2 (0.5) 13.7 (0.4) 13.7 (0.4) 13.4 (0.4) 13.0 (0.4) .004
Gait speed, m/s
Model 1 0.64 (0.01) 0.64 (0.01) 0.64 (0.01) 0.65 (0.01) 0.66 (0.01) .03
Model 2 0.64 (0.01) 0.64 (0.01) 0.65 (0.01) 0.66 (0.01) 0.66 (0.01) .10
6-minute walking distance, m
Model 1 276.1 (5.4) 300.6 (5.0) 303.2 (4.8) 309.4 (5.0) 309.7 (4.9) ,.0001
Model 2 280.3 (5.3) 301.8 (4.8) 304.5 (4.7) 309.9(4.8) 309.9 (4.7) .0002
Handgrip strength, kg
Model 1 22.3 (0.3) 23.3 (0.3) 25.5 (0.3) 23.9 (0.3) 23.0 (0.3) .10
Model 2 22.5 (0.3) 23.3 (0.3) 23.6 (0.3) 24.0 (0.3) 22.9 (0.3) .25
Notes: Adjusted mean values were obtained using the GLM procedure. Model 1 was adjusted for confounder variables (age, BMI, smoking habit, regular physical
activity, season, depression, cognitive status, glomerular filtration rate (according to the MDRD formula). Model 2 was adjusted for the variables in Model 1 plus the
covariates cardiovascular diseases, osteoarticular disease, COPD, and visual impairment;
SE= standard error.
doi:10.1371/journal.pone.0034950.t005
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25OHD levels up to 100 nmol/L, most of the improvement
occurring at concentrations ranging from 50 to approximately
75 nmol/L. Handgrip strength improved in men with increasing
level of vitamin D up to 100 nmol/L. The 6 mW distance
continued to increase up to 25OHD serum levels of 100 nmol/L
in both genders. No further significant improvements in these four
motor performances were seen for 25OHD levels .100 nmol/L,
in both genders.
Discussion
The association between vitamin D and performance tests
exploring mobility impairments has become a clinically hot topic
in the last two decades.
In our large, population-based sample of community-dwelling
Italian elderly subjects, we found a significant positive association
between 25OHD concentrations and 4 of the 6 performance tests
habitually used to assess mobility impairment. The association was
strong for TCS, gait speed, 6 mW distance and handgrip strength.
After controlling for several confounders, 25OHD levels were
clearly associated with TCS results in women, but not in men, and
with gait speed and handgrip strength only in men.
Such gender-related differences are probably explained by the
significantly higher 25OHD levels seen in men, who were less
likely to have vitamin D deficiency than women. This large sex-
difference in 25OHD levels between genders is not so unusual, as
reported in previous studies [17]. In the Longitudinal Aging Study
Amsterdam (LASA), longer times to complete the TCS were only
observed in participants with 25OHD ,50 nmol/L [18]. In our
Table 6. Adjusted estimates of physical performance mean values [mean (SE)] by serum 25-hydroxyvitamin D (25OHD) in men: the
Pro.V.A Study.
MALE 25OHD quintiles (nmol/L)
#53 .53 & #79 .79 & #103 .103 & #143 .143 p for trend
5 timed chair stands, sec
Model 1 13.1 (0.5) 11.4 (0.5) 12.1 (0.4) 11.4 (0.4) 11.6 (0.4) .05
Model 2 13.0 (0.5) 11.4 (0.5) 12.0 (0.4) 11.5 (0.4) 11.6 (0.4) .08
Gait speed, m/s
Model 1 0.71 (0.01) 0.76 (0.01) 0.78 (0.01) 0.77 (0.01) 0.77 (0.01) .0001
Model 2 0.72 (0.01) 0.76 (0.01) 0.78 (0.01) 0.77 (0.01) 0.77 (0.01) .0006
6-minute walking
distance, m
Model 1 330.3 (7.6) 362.1 (7.2) 361.9 (6.8) 379.0 (6.7) 378.6 (6.6) ,.0001
Model 2 334.6 (7.4) 362.6 (6.9) 366.0 (6.6) 376.4 (6.5) 376.6 (6.3) ,.0001
Handgrip strength, kg
Model 1 34.7 (0.6) 34.8 (0.5) 35.1 (0.5) 36.6 (0.5) 35.9 (0.5) .01
Model 2 34.8 (0.6) 34.8 (0.5) 35.3 (0.5) 36.5 (0.5) 35.9 (0.5) .03
Notes: Adjusted mean values were obtained using the GLM procedure. Model 1 was adjusted for confounder variables (age, BMI, smoking habit, regular physical
activity, season, depression, cognitive status, glomerular filtration rate (according to the MDRD formula). Model 2 was adjusted for the variables in Model 1 plus the
covariates cardiovascular diseases, osteoarticular disease, COPD, and visual impairment;
SE= standard error.
doi:10.1371/journal.pone.0034950.t006
Figure 1. Loess regression plots of 5 timed chair stands
measure (seconds) by 25-hydroxyvitamin D (25OHD) concen-
trations; straight line–for women and diamond line ee for
men.
doi:10.1371/journal.pone.0034950.g001
Figure 2. Loess regression plots gait speed (meter/seconds) by
25-hydroxyvitamin D (25OHD) concentrations; straight line–
for women and diamond line ee for men.
doi:10.1371/journal.pone.0034950.g002
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50 nmol/L, and this might explain why an association with TCS
in this cohort was only seen in women.
A slower walking speed coinciding with 25OHD levels
,50 nmol/L has already been reported too [10,11,18]. In our
study, gait speed increased with serum 25OHD levels in both
genders in the unadjusted models, but after controlling for
confounders, this association persisted in men but not in women.
Unfortunately, we cannot compare our results with those of other
cross-sectional studies because gender-specific analyses are often
unavailable and gait speed is not always considered as a measure
in its own right, but scored as part of the Short Physical
Performance Battery [11,18,20].
The Rancho Bernard Study found vitamin D status associated
with handgrip strength in elderly men, but not in older women
[17], whereas in Zamboni et al [27], 25OHD ,40 nmol/ml
correlated with arm strength in women, but not in men.
Differences vis-a `-vis other studies might be explained by the
larger number of potential confounders for which our analyses
were adjusted. Another, more likely explanation for all the sex-
related differences found in our study is that men might have more
preserved muscle strength than women of the same age, therefore
women are already below strength and speed thresholds at which
vitamin D might have a significant impact. Other potential
mechanisms, such as differences in vitamin D receptor gene
polymorphisms, might also be behind the sex-specific differences
identified [28].
Despite the above mentioned differences in performance and
serum 25OH levels, the ‘‘pattern’’ of the association between
vitamin D concentrations and performance measures is similar in
both genders, so that the lower the 25OHD level, the lower the
observed performance.
Among all the performance measures considered, the 6 mW
distance wasthemotortestmoststronglyrelatedtovitaminDstatus
in both genders. Results in the 6 mW test, regarded as a measure of
aerobic capacity, have recently been correlated with cardiovascular
risk [19,29], while the relationship between vitamin D and the
cardiovascular system is still unclear. Ours is the first study to be
performed on a large sample of elderly individuals, confirming the
linear associationbetween25OHDlevelsandthe 6 mWdistancein
both genders, even after adjusting for numerous confounders.
Serum 25OHD concentrations might therefore be able to predict
theaerobiccapacityofelderlysubjects:thehigherthevitaminlevels,
the higher the tolerance of exercise.
In our study, higher vitamin D serum levels are clearly associated
with higher prevalence of regular physical activity and lower
frequency of disease. In this sample of elderly subjects one of the
most practiced physical activities was gardening (details not shown).
We might suppose that this out-door activity might be related to
highersun-exposition,leadingtohigherserumlevelsof25OHD.On
the other hand, regular physical activity was stated by the healthiest
elderly subjects, with the lowest prevalence of comorbidity. Given
that the cross-sectional design of this study does not allow the
knowledgeofsequentialevents,vitaminDlevelsmightbecautiously
interpreted as a biomarker of good health status and good quality of
life.
OurstudydidnotconfirmtheassociationbetweenvitaminDand
staticbalancetestsorquadricepsstrength[16,30,31].Inafewcross-
sectional studies, an impaired static balance was only found in
women with serum 25OHD levels ,25 nmol/L [10,18,32], while
severalotherstudiesenrollingelderlysubjectswithhighervitaminD
levels failed to demonstrate any association between 25OHD
concentrationsandthetandemtest.Interventionalstudiesalsofailed
to show any significant improvement in static balance after vitamin
D supplementation [16]. Similar discrepancies have been found for
quadriceps strength, with which several studies failed to show any
association with 25OHD levels [13–16]. The results from EPIDOS
study confirmed that leg extensor strength was associated with age,
sex and BMI, but not with 25OHD or PTH concentrations [13].
Given the above-mentioned published reports, our results confirm
the lack of any association between vitamin D levels and quadriceps
strength, highlighting the complexity of this poorly understood
relationship.
Inourstudy, loessanalysesconfirmedthat25OHDlevels asclose
as 100 nmol/l are clearly associated in elderly people with a faster
walking time, better performances in rising from a chair, higher
upper limb strength, and greater aerobic capacity. Thresholds for
adequate vitamin D have already been defined, but they are
generally based on PTH levels, not on physical performance
outcomes. One study drawn from the NHANES III data concluded
that it was desirable to reach 25OHD concentrations of at least
40 nmol/L for optimal lower extremity function [11]. Some have
suggested that older adults should be supplemented to maintain
25OHD levels at 70 nmol/L at least [18]. Therefore defining
adequate 25OHD thresholds for both muscle skeletal and extra
skeletal outcomes is more than a challenge. In our study, the
identified vitamin D threshold for physical performance outcome
Figure 3. Loess regression plots of 6-minute walking distance
(meters) by 25-hydroxyvitamin D (25OHD) concentrations;
straight line–for women and diamond line ee for men.
doi:10.1371/journal.pone.0034950.g003
Figure 4. Loess regression plots of handgrip strength (kg) by
25-hydroxyvitamin D (25OHD) concentrations; straight line–
for women and diamond line ee for men.
doi:10.1371/journal.pone.0034950.g004
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with Bischoff-Ferrari et al [11], we found no significant decline in
performance among subjects with the highest of 25OHD levels,
going against any hypothesis that higher vitamin D concentrations
mightbetoxictomotorfunction.Howeverforupperlevelsofserum
25OHD sparse data are available, particularly regarding long-term
effectsofchronicallyhighconcentrations,thusamarginofsafetyfor
public health recommendation is prudent. According to the last
report of the Institute of Medicine on the tolerable upper vitamin D
levels, serum 25OHD concentration above 125 nmol/L should
raise concerns among clinicians about potential adverse effect,
particularly on extra skeletal outcomes [33].
The present study has limitations. A participation bias probably
attenuated the results, since the participants were probably the
healthiest. This might explained why in our population-based
sample vitamin D levels were significantly higher than those
reported in previous studies on elderly Italian subjects [34,35].
Differences in methods used to measure 25OHD make it difficult to
compare optimal levels with those observed in other studies [36],
although methodological differences would not affect the linear
association seen between 25OHD and physical function. Moreover
the cross-sectional design of our study did not allow us to formulate
hypothesis on the causality of the relationship between vitamin D
and performance.
The mainstrengths of our study lie inits population-based design
and large sample size, comprising a proportion of men and women
representative of the general older population in northern Italy. A
further strength relates to the large number of confounders and
adjudicated diseases investigated, and the numerous performance
tests conducted to explore different dimensions of mobility.
In conclusion, serum concentrations of 25OHD close to
100 nmol/L seem to be associated to greater benefit for musculo-
skeletalfunctionsinourelderlycommunity-dwellingsubjects.Given
the high prevalence of vitamin D insufficiency in the elderly
population of northern Italy, ageing people should be given
supplementation to keep their 25OHD levels as nearest as possible
to this threshold, in order to preserve their physical performance.
Besides additional researches are needed for consensus on 25OHD
threshold in order to avoid problems of both under and over-
treatment.
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